BioCardia, Inc. — Form 8-K Summary
Reporting date: October 7, 2026. The 8-K reports an event under Item 8.01, not quarterly or annual financial results.
Business context
BioCardia said it issued a press release announcing that it presented the CardiAMP HF II trial design at the Heart Failure Society of America Annual Scientific Meeting. The filing identifies the press release as Exhibit 99.1, but its contents are not included in the provided text.
Financial information
The filing text provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no prior-period comparison.
Outlook, risks, and unusual items
No guidance, financial outlook, trial-design details, clinical results, risks, or contingencies are described in the provided filing text. The company states that the Item 8.01 information is furnished and is not deemed filed for Exchange Act Section 18 purposes, subject to the exceptions stated in the filing.
Important facts to verify
- Review Exhibit 99.1 for the CardiAMP HF II trial design and any additional company commentary.
- Confirm the trial’s objectives, design, enrollment, endpoints, timeline, and regulatory status from the press release or other company disclosures.
- Do not interpret this 8-K as reporting financial results; no financial-period data is provided.